Kintara Therapeutics Inc
NASDAQ:KTRA

Watchlist Manager
Kintara Therapeutics Inc Logo
Kintara Therapeutics Inc
NASDAQ:KTRA
Watchlist
Price: 6.3 USD -16.43% Market Closed
Market Cap: 266.4m USD
Have any thoughts about
Kintara Therapeutics Inc?
Write Note

Kintara Therapeutics Inc
Total Equity

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Kintara Therapeutics Inc
Total Equity Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Equity CAGR 3Y CAGR 5Y CAGR 10Y
Kintara Therapeutics Inc
NASDAQ:KTRA
Total Equity
$3.8m
CAGR 3-Years
-29%
CAGR 5-Years
14%
CAGR 10-Years
16%
Abbvie Inc
NYSE:ABBV
Total Equity
$6B
CAGR 3-Years
-24%
CAGR 5-Years
N/A
CAGR 10-Years
3%
Gilead Sciences Inc
NASDAQ:GILD
Total Equity
$18.4B
CAGR 3-Years
-5%
CAGR 5-Years
-2%
CAGR 10-Years
3%
Amgen Inc
NASDAQ:AMGN
Total Equity
$7.5B
CAGR 3-Years
-3%
CAGR 5-Years
-7%
CAGR 10-Years
-11%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Total Equity
$15.6B
CAGR 3-Years
18%
CAGR 5-Years
24%
CAGR 10-Years
30%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Total Equity
$29.3B
CAGR 3-Years
19%
CAGR 5-Years
23%
CAGR 10-Years
28%
No Stocks Found

Kintara Therapeutics Inc
Glance View

Market Cap
266.4m USD
Industry
Biotechnology

Kintara Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of new cancer therapies. The company is headquartered in San Diego, California and currently employs 4 full-time employees. The company went IPO on 2016-07-12. The firm is developing two late-stage, Phase III-ready therapeutics. The firm's two lead product candidates are VAL-083 and REM-001. VAL- 083 is a validated, Deoxyribonucleic acid (DNA)-targeting agent, for the treatment of drug-resistant solid tumors such as glioblastoma multiforme (GBM) and potentially other solid tumors, including ovarian cancer, non-small cell lung cancer (NSCLC) and diffuse intrinsic pontine glioma (DIPG). REM-001 is a late-stage photodynamic therapy (PDT) for the treatment of cutaneous metastatic breast cancer (CMBC). The firm is carrying out various clinical trials on brain tumor and solid tumor.

KTRA Intrinsic Value
6.92 USD
Undervaluation 9%
Intrinsic Value
Price

See Also

What is Kintara Therapeutics Inc's Total Equity?
Total Equity
3.8m USD

Based on the financial report for Jun 30, 2024, Kintara Therapeutics Inc's Total Equity amounts to 3.8m USD.

What is Kintara Therapeutics Inc's Total Equity growth rate?
Total Equity CAGR 10Y
16%

Over the last year, the Total Equity growth was 415%. The average annual Total Equity growth rates for Kintara Therapeutics Inc have been -29% over the past three years , 14% over the past five years , and 16% over the past ten years .

Back to Top